Meeting News CoverageVideo

VIDEO: Gene signature may guide adjuvant chemotherapy use in early-stage breast cancer

NEW ORLEANS — Lajos Pusztai, MD, DPhil, chief of breast medical oncology and co-director of the genetics, genomics and epigenetics program at Yale Cancer Center, spoke with HemOnc Today about the potential implications of the MINDACT trial.

Results of the randomized phase 3 trial showed a 70-gene signature called MammaPrint can help predict which patients with early-stage breast cancer will derive the most benefit from adjuvant chemotherapy.

See more from American Association for Cancer Research Annual Meeting